Keyphrases
Anticancer Immunotherapy
12%
Bone Marrow
31%
Bone Marrow Niche
12%
Cell-free DNA (cfDNA)
37%
Cell-free RNA
12%
Circulating Tumor DNA (ctDNA)
15%
Co-culture System
12%
Copy number Aberrations
12%
Copy number Variation
15%
Diagnostic Biomarker
12%
Diffuse Intrinsic Pontine Glioma
12%
Disease Monitoring
12%
Disseminated Infection
12%
DNA Markers
12%
Droplet Digital PCR (ddPCR)
36%
Hypermethylated
12%
Liquid Biomarkers
12%
Liquid Biopsy
45%
Marker Panel
14%
Mesenchymal Stromal Cells
12%
Metastatic Bone
12%
Minimal Residual Disease
27%
MiR-371a-3p
12%
Molecular Detection
12%
Multiplex RT-PCR
12%
Neuroblastoma
88%
Neuroblastoma Cells
15%
Organoids
12%
Patient Samples
18%
Patient-specific
12%
Pediatric Cancer Patients
12%
Pediatric Patients
15%
Pediatric Rhabdomyosarcoma
12%
Pediatric Tumors
39%
Peripheral Blood
13%
Personalised Assessment
12%
Prognostic Biomarker
12%
Quantitative PCR
28%
RASSF1A
50%
Rhabdomyosarcoma
25%
Risk Stratification
12%
RNA Markers
27%
Sensitive Detection
15%
Specific Detectivity
12%
Targeted Locus Amplification
12%
Technical Potential
12%
Testicular Germ Cell Tumor
12%
Tumor
19%
Tumor Organoids
15%
Tumor Patients
12%
Medicine and Dentistry
Biological Marker
25%
Biopsy Technique
6%
Cell-Free DNA
45%
Chorionic Gonadotropin
5%
CHRNA3
6%
Circulating Tumor DNA
12%
Dentigerous Cyst
5%
Diagnosis
19%
Disease
14%
Disseminated Disease
12%
DNA Marker
12%
Droplet Digital Polymerase Chain Reaction
29%
Event Free Survival
11%
Ewing Sarcoma
6%
Ex Vivo
5%
Fusion Gene
6%
Ganglioneuroblastoma
100%
Germinoma
12%
Immunotherapy
12%
Intracranial Tumor
5%
Liquid Biopsy
58%
Localized Disease
5%
Malignant Neoplasm
5%
Mesenchymal Stem Cell
12%
Messenger RNA
46%
Metastatic Carcinoma
13%
Minimal Residual Disease
29%
Neoplasm
46%
Neuroblastoma Cell
14%
Organoid
14%
Patient with Neuroblastoma
24%
Pediatric Cancer
27%
Pediatrics
41%
Pediatrics Patient
16%
Pontine Glioma
12%
Quantitative Reverse Transcription Polymerase Chain Reaction
14%
Real-Time Polymerase Chain Reaction
15%
Recurrent Disease
5%
Reduced Representation Bisulfite Sequencing
6%
Rhabdomyosarcoma
34%
Risk Stratification
12%
RNA Directed DNA Polymerase
8%
Sensitive Detection
14%
Size-Exclusion Chromatography
8%
Solid Malignant Neoplasm
25%
Tumor Marker
8%
Whole Genome Sequencing
6%
Wilms' Tumor
8%